Literature DB >> 15544450

Immunization for persons infected with human immunodeficiency virus.

Chitsanu Pancharoen1, Jintanat Ananworanich, Usa Thisyakorn.   

Abstract

Immunization is an important measure to protect HIV-infected children and adults against certain vaccine preventable diseases. However, the antibody response, which is associated with the level of CD4+ T cell count, is frequently impaired in this group of patients. Certain vaccines enhance virus replication and transiently increase HIV viral load. Theoretically, vaccination should be given before the immune status of the patients is suppressed. Inactivated vaccines are generally safe and are beneficial for HIV-infected patients. These vaccines should be administered at appropriate age recommended for immunocompetent individuals. Live vaccines should be used with caution since some of the vaccines may be harmful to patients with severe immunologic suppression. Recommendations for immunization in HIV-infected patients may differ from country to country, depending on the availability and affordability of each vaccine, and the prevalence of each preventable disease. Vaccine trial in HIV-infected patients is needed in order to establish the most appropriate vaccine recommendation for this group of patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544450     DOI: 10.2174/1570162043351084

Source DB:  PubMed          Journal:  Curr HIV Res        ISSN: 1570-162X            Impact factor:   1.581


  3 in total

Review 1.  Antibody-secreting B cells in HIV infection.

Authors:  Nicole A Doria-Rose; Mark Connors
Journal:  Curr Opin HIV AIDS       Date:  2009-09       Impact factor: 4.283

2.  Decreased mutation frequencies among immunoglobulin G variable region genes during viremic HIV-1 infection.

Authors:  Elisabeth Bowers; Ronald W Scamurra; Anil Asrani; Lydie Beniguel; Samantha MaWhinney; Kathryne M Keays; Joseph R Thurn; Edward N Janoff
Journal:  PLoS One       Date:  2014-01-07       Impact factor: 3.240

3.  HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization.

Authors:  Mathurin C Tejiokem; Ionela Gouandjika; Lydie Béniguel; Marie-Claire Endegue Zanga; Gilbert Tene; Jean C Gody; Elisabeth Njamkepo; Anfumbom Kfutwah; Ida Penda; Catherine Bilong; Dominique Rousset; Régis Pouillot; Frédéric Tangy; Laurence Baril
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.